Expert Talks With Mr Steven Yatomi Clarke, CEO and Managing Director of Prescient Therapeutics

Welcome you all to “Executive corner - Expert talks- 20 mins Round up with Mr. Steven Yatomi-Clarke – CEO and Managing Director of Prescient Therapeutics.” 

Prescient Therapeutics Ltd is a small molecule drug development company focused on new cancer drugs. The company's lead compound, PTX-200, inhibits the AKT tumor survival pathway. The company's second compound, PTX-100, blocks a cancer growth enzyme known as geranylgeranyltransferase type 1.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK